Head-To-Head Analysis: PROCEPT BioRobotics (NASDAQ:PRCT) vs. Kewaunee Scientific (NASDAQ:KEQU)

Kewaunee Scientific (NASDAQ:KEQU) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Profitability

This table compares Kewaunee Scientific and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kewaunee Scientific	2.97%	11.61%	4.82%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

Earnings and Valuation

This table compares Kewaunee Scientific and PROCEPT BioRobotics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kewaunee Scientific	$282.00 million	0.34	$9.62 million	$2.76	12.12
PROCEPT BioRobotics	$308.05 million	3.57	-$95.57 million	($1.94)	-9.90

Kewaunee Scientific has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Kewaunee Scientific has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Institutional & Insider Ownership

32.7% of Kewaunee Scientific shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 14.1% of Kewaunee Scientific shares are held by company insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Kewaunee Scientific and PROCEPT BioRobotics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kewaunee Scientific	0	1	0	0	2.00
PROCEPT BioRobotics	2	9	2	3	2.38

PROCEPT BioRobotics has a consensus target price of $25.50, indicating a potential upside of 32.81%. Given PROCEPT BioRobotics’ stronger consensus rating and higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Kewaunee Scientific.

Summary

PROCEPT BioRobotics beats Kewaunee Scientific on 8 of the 15 factors compared between the two stocks.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.